Sirukumab


Sirukumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It acts against the proinflammatory cytokine Interleukin 6.
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor

Clinical trials

Rheumatoid arthritis

It has started clinical trials. and reported some phase II results.
In December 2015 three phase III trials were collecting data.
By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.

Other

The drug is currently in phase II clinical trials for the treatment of depression.